| Page 56 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?

Author(s): 
Bewersdorf JP, Zeidan AM
Primary Author: 
Bewersdorf JP
Journal Title: 
Expert Review of Hematology
Original Publication Date: 
Sep 2020

Introduction: Hypomethylating agents (HMA) remain the mainstay of treatment for patients with higher-risk

Bone Marrow Disease(s): 

Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SAAWP o

Author(s): 
ElGohary G, El Fakih R, de Latour R, Risitano A, Marsh J, Schrezenmeier H, Gluckman E, Höchsmann B, Pierri F, Halkes C, Alzahrani H, De la Fuente J, Cesaro S, Alahmari A, Ahmed SO, Passweg J, Dufour C, Bacigalupo A, Aljurf M
Primary Author: 
ElGohary G
Journal Title: 
Bone Marrow Transplantation
Original Publication Date: 
Oct 2020

Bone Marrow Disease(s): 

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.

Author(s): 
Peipert JD, Kulasekararaj AG, Gaya A, Langemeijer SMC, Yount S, Gonzalez-Fernandez FA, Ojeda Gutierrez E, Martens C, Sparling A, Webster KA, Cella D, Tomazos I, Ogawa M, Piatek CI, Wells R, Sicre de Fontbrune F, Röth A, Mitchell L, Hill A, Kaiser K
Primary Author: 
Peipert JD
Journal Title: 
PloS One
Original Publication Date: 
Sep 2020

Background: Eculizumab has transformed management of

Bone Marrow Disease(s):